VRT-325

VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the ΔF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote ΔF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi[1].

Product Specifications

CAS Number

[815592-21-3]

Product Name Alternative

4-Hydroxy-TEMPO-d17,15N

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CFTR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/vrt-325.html

Purity

99.15

Smiles

CC(N1CCN(CC1)S(=O)(C2=CC=C(C=C2)OC)=O)C3=NC(OC4CCCCC4)=C5C=CC=CC5=N3

Molecular Formula

C27H34N4O4S

Molecular Weight

510.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Van Goor F, et al. Rescue of ﾎ508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules[J]. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2006, 290 (6) : L1117-L1130.